Literature DB >> 1701304

An HIV-1 and HIV-2 cross-reactive cytotoxic T-cell epitope.

D F Nixon1, S Huet, J Rothbard, M P Kieny, M Delchambre, C Thiriart, C R Rizza, F M Gotch, A J McMichael.   

Abstract

The HLA-B27-restricted HIV gag cytotoxic T-lymphocyte (CTL) epitope, 265-279, is highly conserved amongst HIV-1 isolates, only one, HIV-1ELI, having a single amino acid substitution. Over the same region HIV-2 differs by five amino acids. As a broadly cross-protective AIDS vaccine should protect against infection from all isolates of HIV-1 and HIV-2, we tested CTL specific for the HIV-1 265-279 epitope with peptide analogues from HIV-1ELI, HIV-2 and two simian immunodeficiency virus (SIV) isolates, and with recombinant vaccinia viruses expressing the respective gag genes, to determine whether there was any cross-reactivity for this CTL epitope. CTL from the HIV-1-infected donor could recognize the HIV-1ELI peptide, the HIV-2 peptide and recombinant vaccinia virus-infected target and one of the two SIV peptide-treated targets. Epitopes that exhibit such cross-reactivity may be valuable in vaccine design.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 1701304     DOI: 10.1097/00002030-199009000-00002

Source DB:  PubMed          Journal:  AIDS        ISSN: 0269-9370            Impact factor:   4.177


  8 in total

Review 1.  Cellular and humoral antigenic epitopes in HIV and SIV.

Authors:  D F Nixon; K Broliden; G Ogg; P A Broliden
Journal:  Immunology       Date:  1992-08       Impact factor: 7.397

2.  Cross-reactions between the cytotoxic T-lymphocyte responses of human immunodeficiency virus-infected African and European patients.

Authors:  D Durali; J Morvan; F Letourneur; D Schmitt; N Guegan; M Dalod; S Saragosti; D Sicard; J P Levy; E Gomard
Journal:  J Virol       Date:  1998-05       Impact factor: 5.103

3.  Cytotoxic T cells from human immunodeficiency virus type 2-infected patients frequently cross-react with different human immunodeficiency virus type 1 clades.

Authors:  A Bertoletti; F Cham; S McAdam; T Rostron; S Rowland-Jones; S Sabally; T Corrah; K Ariyoshi; H Whittle
Journal:  J Virol       Date:  1998-03       Impact factor: 5.103

4.  Anti-retroviral strategies for AIDS and related diseases.

Authors:  M A Wainberg; A Dascal; J Mendelson
Journal:  Can J Infect Dis       Date:  1991

5.  Two MHC class I molecules associated with elite control of immunodeficiency virus replication, Mamu-B*08 and HLA-B*2705, bind peptides with sequence similarity.

Authors:  John T Loffredo; John Sidney; Alex T Bean; Dominic R Beal; Wilfried Bardet; Angela Wahl; Oriana E Hawkins; Shari Piaskowski; Nancy A Wilson; William H Hildebrand; David I Watkins; Alessandro Sette
Journal:  J Immunol       Date:  2009-06-15       Impact factor: 5.422

6.  Three epitopic peptides of the simian immunodeficiency virus Nef protein recognized by macaque cytolytic T lymphocytes.

Authors:  I Bourgault; A Venet; J P Levy
Journal:  J Virol       Date:  1992-02       Impact factor: 5.103

7.  Induction of a major histocompatibility complex class I-restricted cytotoxic T-lymphocyte response to a highly conserved region of human immunodeficiency virus type 1 (HIV-1) gp120 in seronegative humans immunized with a candidate HIV-1 vaccine.

Authors:  R P Johnson; S A Hammond; A Trocha; R F Siliciano; B D Walker
Journal:  J Virol       Date:  1994-05       Impact factor: 5.103

8.  Multispecific and heterogeneous recognition of the gag protein by cytotoxic T lymphocytes (CTL) from HIV-infected patients: factors other than the MHC control the epitopic specificities.

Authors:  F Buseyne; G Janvier; B Fleury; D Schmidt; Y Rivière
Journal:  Clin Exp Immunol       Date:  1994-09       Impact factor: 4.330

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.